Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3786920 | 0.88 | ERN1 (0.38) | ERN1NPBWR1GRM5 | |
| SCHEMBL3684681 | 0.88 | ERN1 (0.38) | ERN1NPBWR1GRM5 | |
| SCHEMBL3689416 | 0.88 | ERN1 (0.41) | ERN1NPBWR1GRM5 | |
| Hydrochloric Acid SCHEMBL3787578 | 0.87 | ERN1 (0.38) | ERN1NPBWR1GRM5 | |
| SCHEMBL3785576 | 0.86 | ERN1 (0.37) | ERN1NPBWR1GRM5 | |
| Hydrochloric Acid SCHEMBL3786905 | 0.85 | ERN1 (0.36) | ERN1NPBWR1GRM5 | |
| SCHEMBL3785390 | 0.85 | ERN1 (0.36) | ERN1NPBWR1GRM5 | |
| SCHEMBL3687351 | 0.84 | ERN1 (0.40) | ERN1NPBWR1 | |
| SCHEMBL3786076 | 0.83 | ERN1 (0.40) | ERN1NPBWR1GRM5 | |
| SCHEMBL13229141 | 0.81 | ERN1 (0.38) | ERN1NPBWR1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010091409-A1 | CERTAIN NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010091409-A1 | CERTAIN NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | ERN1 237/4885NPBWR1 3024/4885GRM5 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.